ニュース

イベント

【公開セミナー】Sin-Hyeog Im, Ph.D.

2024年10日17日

Sin-Hyeog Im 博士

Credits: WPI-Bio2Q

セミナー参加者と。

Credits: WPI-Bio2Q

Sin-Hyeog Im 博士(左）と長谷耕二教授 (Bio2Q Affiliated PI、右)

Credits: WPI-Bio2Q

慶應義塾大学ヒト生物学-微生物叢-量子計算研究センター（WPI-Bio2Q）は、以下のとおり、公開セミナーを開催しました。

日時	2024年10月11日（金）17:30 -18:30
場所	慶應義塾大学信濃町キャンパス総合医科学研究棟１Fラウンジ　＜現地開催のみ＞
演題	Microbiome Therapeutics for Inflammatory Disorders and Cancer
講演者	Sin-Hyeog Im, Ph.D. Professor Department of Life Sciences, Pohang University of Science and Technology, Korea
言語	英語

ポスター (PDF)

講演要旨

Microbiome Therapeutics for Inflammatory Disorders and Cancer
“Our immune system induces active immunity against diverse pathogens while suppressing destructive hyper-immune responses against innocuous antigens. This immune homeostasis is maintained by concerted crosstalk between genetic factors and environmental cues, including intestinal gut microbiota. Dysregulation of the commensal flora is closely linked to functional changes in the immune and neuronal systems. Subsequently, it contributes to the development of immune disorders (such as autoimmunity and allergies), neuronal disorders (depression, autism spectrum disorders), and metabolic syndromes. Moreover, altered gut microbiota affects differential responsiveness to immune checkpoint inhibitors targeting PDL1/PD-1 and CTLA4. The candidates of microbiome therapeutics include bioactive molecules derived from the microbiome (metabolites and cellular components) and the bug itself (live biotherapeutic products, LBP).
To identify anti-inflammatory and immune-stimulatory microorganisms, we have developed a platform screening system, AvatiomeTM, an innovative pre-clinical model system that mimics the human body’s immune system and microbiome. Avatiome ™ incorporates up-to-date technologies such as immunophenotyping, single-cell transcriptomics, and artificial intelligence (AI) systems to develop novel therapeutics targeting intractable neuronal, systemic inflammatory diseases and cancers. Through the screening system, we have identified immunostimulatory (IMB001) or immunoregulatory (IMB002) microorganisms and further defined the effector molecules that recapitulate the functionality of whole bacteria. I will discuss the current status of microbiome therapeutics and our work on identifying IMB002 and IMB001, which show anti-inflammatory and anti-cancer activities, respectively. Moreover, I will also discuss the underlying mechanism of action of the effector molecules in the diverse pre-clinical models and potential therapeutic applications.”

関連論文

Cell surface polysaccharides of Bifidobacterium bifidum induce Foxp3+ regulatory T cells. Science Immunology. 2018 Oct 19;3(28). pii: eaat6975. doi: 10.1126/sciimmunol.aat6975.
Intestinal Microbiota Controls Acute Kidney Injury Severity by Immune Modulation. Kidney Int. 2020: S0085-2538(20)30553-6
Probiotics-derived metabolite ameliorates skin allergy by promoting differentiation of FOXP3+ regulatory T cells. J Allergy Clin Immunol 2021. 147 (4), 1517-1521
Structural specificities of cell surface β-glucan polysaccharides determine commensal yeast-mediated immuno-modulatory activities. Nature Communications. 2021. June 14; 12(1):3611
A dietary commensal microbe enhances anti-tumor immunity by activating tumor macrophages to sequester iron. Nature Immunology. 2024 May;25(5):790-801